Larimar Therapeutics Inc

Larimar Therapeutics Inc

LRMR

Get informed when a big investor buys or sells

+ Follow
Market Cap$434.23M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Larimar Therapeutics IncLarimar Therapeutics Inc-2.1--136%--
$8.00

Target Price by Analysts

91.8% upsideLarimar Therapeutics Target Price DetailsTarget Price
$1.12

Current Fair Value

73.3% downside

Overvalued by 73.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$434.23 Million
Enterprise Value$346.50 Million
Dividend Yield$- (-)
Earnings per Share$-2.27
Beta0.75
Outstanding Shares103,882,937

Return

Return on Equity-135.50%ROE
Return on Assets-104.42%
Return on Invested Capital-135.29%

Valuation & Multiples

P/E Ratio-2.1P/E Ratio
PEG-8.33PEG
Price to Sales-Price to Sales
Price to Book Ratio4.17Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-1.95
Enterprise Value to Net Income-3
Total Debt to Enterprise0.01
Debt to Equity0.04Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 13, 2026
EPS Estimate
$-0.39
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
November 5, 2026
EPS Estimate
$-0.39
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.6478 52.66%
Total Calls477,000 230.33%
Total Puts309,000 1665.71%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %103.02% 3.35%
Total Invested$394.80M 42.52%
Investors Holding170 32.00%

ESG Score

No data

About Larimar Therapeutics Inc